Exciting research projects and novel therapies
Infections continue to threaten human health as pathogenic organisms outsmart available therapies with remarkable genetic versatility. Fortunately, microbial versatility is matched by the flexibility of the host immune system, which provides a rich source of novel therapeutic concepts.
Our therapeutic strategy is to find and develop substances that strengthen the immune system.
Rather than drugs killing the bacteria directly the patient’s immune system is empowered to deal with the bacteria.
Our goal is to provide a different molecular framework for the treatment of bacterial infections; much needed to combat antibiotic resistance.
IL1-receptor antagonists
IL-1 receptor antagonists to treat acute infections and prevent tissue damage
NK1R-inhibitors
A nerve cell receptor antagonist prevents prevents pain and tissue damage during acute infections
RNA Pol II inhibitors
A small molecule from ”nice bacteria” prevents over-activation of immunity and reduces inflammation
IRF7 inhibitors
New molecular tools to inhibit ‘’bad’’ inflammation in infected tissue and reduce the risk of sepsis
Scientific Publications
Immunomodulation therapy offers new molecular strategies to treat UTI
Butler, D. et al. Review Article, Nature Reviews Urology, doi:10.1038/s41585-022-00602-4 (2022).
PDF: NRU 2022
Immunomodulation – a molecular solution to treating patients with severe bladder pain syndrome?
Wullt, B. et al. European Urology Open Science, 31, 49-58, doi:10.1016/j.euros.2021.07.003 (2021).
Collateral effects of deletion of nlpD on rpoS and rpoS-dependent genes. Reply.
Ambite, I. et al. Letter to the Editor, The Journal of Clinical Investigation 131(18):e153234 doi:10.1172/JCI153234 (2021).
PDF: JCI letter to the Editor 2021
Molecular determinants of disease severity in urinary tract infection
Ambite, I. et al. Review Article, Nature Reviews Urology 18, 468–486, doi:10.1038/s41585-021-00477-x (2021).
PDF: NRU 2021
Active bacterial modification of the host environment through RNA Polymerase II inhibition
Ambite, I. et al. The Journal of Clinical Investigation 131(4), e140333, doi:10.1172/JCI140333 (2021).
PDF: JCI 2021
Neuroepithelial control of mucosal inflammation in acute cystitis
Butler, D.S.C. et al. Scientific Reports 8, 11015, doi:10.1038/s41598-018-28634-0 (2018).
PDF: Sci reports 2018
IRF7 inhibition prevents destructive innate immunity—A target for nonantibiotic therapy of bacterial infections
Puthia, M. et al. Science Translational Medicine 8(336), 336ra59, doi:10.1126/scitranslmed.aaf1156 (2016).
PDF: Sci Trans Med 2016
Molecular basis of acute cystitis reveals susceptibility genes and immunotherapeutic targets.
Ambite, I. et al. PLoS Pathogens 12(10), e1005848, doi:10.1371/journal.ppat.1005848 (2016).
PDF: Plos Pathogens 2016
Bacterial control of host gene expression through RNA polymerase II
Lutay, N. et al. The Journal of Clinical Investigation 123(6), 2366-79, doi:10.1172/JCI6645 (2013).
PDF: JCI 2013